Journal
BIOCHEMICAL PHARMACOLOGY
Volume 164, Issue -, Pages 64-73Publisher
PERGAMON-ELSEVIER SCIENCE LTD
DOI: 10.1016/j.bcp.2019.03.036
Keywords
Exogenous surfactant; Drug delivery; Acute Respiratory Distress Syndrome (ARDS); Bacterial Pneumonia; Computer modeling; Wet bridge transfer system
Categories
Funding
- Brazilian National Council for Scientific and Technological Development [CNPq - 465259/2014-6]
- Coordination for the Improvement of Higher Education Personnel (CAPES)
- National Institute of Science and Technology Complex Fluids (INCT-FCx)
- Sao Paulo Research Foundation [FAPESP- 2014/50983-3]
- Ontario Thoracic Society
- Lawson Health Research Institute
- Ontario Graduate Studentship
Ask authors/readers for more resources
As an organ system, the lung has unique advantages and disadvantages for localized drug delivery. Its direct contact with the external environment allows for the upper airways to be easily accessible to intrapulmonary delivery. However, its complex branching structure makes direct delivery to the peripheral airways challenging. This review will discus the utility of exogenous surfactant, a lipoprotein complex currently used to treat neonatal respiratory distress syndrome, as a carrier for pulmonary therapeutics to enhance the delivery of these drugs to the deeper regions of the lung. The focus is to provide an update on the many tools available to develop new surfactant-based therapeutics using computer modeling, in vitro approaches, and in vivo testing, which may ultimately lead to clinical trials. Two clinical conditions, Acute Respiratory Distress Syndrome and Bacterial Pneumonia are utilized throughout as prototypical examples of pulmonary conditions in which surfactant drug combination may be beneficial. Consequently, the pharmaceuticals discussed are primarily those with antimicrobial or anti-inflammatory activities.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available